Volume 111 Issue 6, December 2025

Read the latest issue. It contains the following articles:
The use of bone-modifying agents in early breast cancer: AIOM Guidelines update and perspectives
Delphi Study on the creation of a Committee of patients, caregivers, and representatives of patient associations
The e-BRAVE study: A prospective web-based cohort and biobank of women carriers of BRCA mutations
An indirect approach to identify the healthcare services for thyroid and melanoma cancer patients in Italy: Epicost-2 project
Association of APOC1 levels and nutritional indices with clinicopathological features and prognostic value in patients with DLBCL
Predicting severe toxicity after head-and-neck cancer RT: Validation of the synergist role of a biological marker and dosimetry
Effects of uniportal 3D video-assisted thoracic surgery lobectomy on postoperative pain and immune function in patients with NSCLC
Medication-related jaw osteonecrosis in metastatic RCC treated with VEGFR-TKIs ± IO and bone agents: A real-world analysis

Abdominal specimen retrieval in endometrial cancer patients with large uteri

Endometrial cancer surgery has a low risk of specimen fragmentation, but removing large uteri can be challenging. This study aimed to assess whether the use of minilaparotomic incision for specimen retrieval compromises the benefits of minimally invasive surgery in endometrial cancer patients with a large uterus or utero-vaginal discrepancy.
This is a retrospective multi-institutional study, including endometrial cancer patients with FIGO 2009 clinical stage I–II, undergoing minimally invasive staging surgery (laparoscopic or robot-assisted) followed by minilaparotomic specimen retrieval. A propensity-matched algorithm was used to compare outcomes of minimally invasive staging with open surgery.

A phase II study of nivolumab plus metformin in pre-treated metastatic renal cell carcinoma patients: NivoMet TWINS-GU002 Study

This study evaluates the activity of nivolumab plus metformin in pre-treated metastatic renal cell carcinoma (mRCC) patients.
The NivoMet TWINS-GU002 Study was a prospective, multicentre, single-arm, phase II trial conducted in pre-treated mRCC patients eligible for nivolumab and without diabetes mellitus. Patients received nivolumab (240 mg every two weeks) plus metformin (500 mg orally twice a day) until disease progression.

Pediatric palliative care in patients with brain tumors: Timing, activation, and management of acute events

The highest percentage of our patients referred to Pediatric Palliative Care (PPC) are those with brain tumors. Of these, we analyzed PPC activation modes and timing, occurrence of acute events during the period of PPC activation, and the time between acute event and death.
During the period 1 January 2010 to 31 October 2023 approximately 1000 Cranial Nervous System (CNS) tumor patients were treated at Fondazione IRCCS Istituto Nazionale dei Tumori in Milan.

Inter-hospital heterogeneity in the authorizations of off-label cancer drugs: A project by Associazione Italiana di Oncologia Medica

This project aimed to describe variability of local evaluations of off-label cancer drug requests by submitting a list of identical requests to different Italian centers.
In October 2024, oncology unit directors listed in the AIOM Libro Bianco were invited to participate, evaluating 11 clinical cases with solid tumors through their internal approval process. Supporting evidence was retrospective in two cases, based on phase II trials in seven, and phase III trials in two. Inter-rater agreement was measured using Fleiss’ kappa.

Predictors of duration of hospital stay for cancer patients admitted due to medical causes: A quality-improvement evaluation

Hospital admission is frequently required in the cancer trajectory. In a context of bed shortage, pressure on Emergency Departments and increasing healthcare costs, promoting actions that contain hospital stay is a priority. We studied the variables able to predict longer hospital stays.
We retrospectively retrieved data on consecutive admissions in our cancer inpatient unit in a 6-month period and assessed individual and clinical variables potentially related with duration of hospital stay through univariate and multivariate analysis.

Volume 111 Issue 5, October 2025

Read the latest issue. It contains the following articles:
The use of bone-modifying agents in early breast cancer: AIOM Guidelines update and perspectives
Delphi Study on the creation of a Committee of patients, caregivers, and representatives of patient associations
The e-BRAVE study: A prospective web-based cohort and biobank of women carriers of BRCA mutations
An indirect approach to identify the healthcare services for thyroid and melanoma cancer patients in Italy: Epicost-2 project
Association of APOC1 levels and nutritional indices with clinicopathological features and prognostic value in patients with DLBCL
Predicting severe toxicity after head-and-neck cancer RT: Validation of the synergist role of a biological marker and dosimetry
Effects of uniportal 3D video-assisted thoracic surgery lobectomy on postoperative pain and immune function in patients with NSCLC
Medication-related jaw osteonecrosis in metastatic RCC treated with VEGFR-TKIs ± IO and bone agents: A real-world analysis

Liquid biopsy in prostate cancer: A multidisciplinary expert consensus statement

BRCA1/2 testing via liquid biopsy has emerged as a critical, minimally invasive alternative to tissue sampling in metastatic castration-resistant prostate cancer (mCRPC), especially in the context of insufficient, inadequate, or unavailable tumor material.
A multidisciplinary panel of 18 Italian experts from 16 leading academic and clinical institutions convened to develop consensus recommendations on BRCA1/2 testing via liquid biopsy.